Literature DB >> 31308471

Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.

Jiang Cao1, Hai Cheng1, Ming Shi2, Gang Wang2, Wei Chen1, Kunming Qi1, Huizhong Li2, Jianlin Qiao3, Jing Zhao1, Qingyun Wu3, Lingyu Zeng3, Guangjun Jing4, Junnian Zheng5,6,7, Kailin Xu8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31308471     DOI： 10.1038/s41375-019-0516-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

Review 1.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 2.  In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  Mol Cancer Ther       Date:  2021-04-26       Impact factor: 6.009

3.  Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment.

Authors:  Dan Liu; Xiyue Xu; Yulian Dai; Xuan Zhao; Shunshun Bao; Wen Ma; Li Zha; Shuci Liu; Yuchen Liu; Junnian Zheng; Ming Shi
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 4.  Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.

Authors:  Yuru Nie; Weiqing Lu; Daiyu Chen; Huilin Tu; Zhenling Guo; Xuan Zhou; Meifang Li; Sanfang Tu; Yuhua Li
Journal:  Biomark Res       Date:  2020-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.